Prasugrel vs. Ticagrelor on Myocardial Injury in STEMI

AORTICA Group61 enrolled

Overview

The investigators propose to perform a randomized clinical trial comparing prasugrel vs. ticagrelor in 60 patients with ST elevation acute myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention. The principal objective of the study would be analyzing the difference in myocardial infarction size measured by cardiac magnetic resonance at 6 months

Dual antiplatelet therapy consisting of aspirin and one of the P2Y12 receptor inhibitors is the mainstay of treatment for patients with ST elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Prasugrel or ticagrelor have actually shown to be superior to clopidogrel improving the prognosis of these patients. However, the industrial interest has avoided any direct comparison between these two antiplatelets. Comparison is of great interest considering that only ticagrelor has shown to significantly reduce mortality. As ticagrelor may exert off-target effects through adenosine-related mechanisms, the investigators aimed to investigate whether ticagrelor reduces myocardial injury to a greater extent than prasugrel in patients with revascularized STEMI. Patients with acute STEMI undergoing primary percutaneous coronary revascularization within 6 hours of chest pain, will be randomized to (1) prasugrel (a 60 mg oral loading and a 10-mg dailiy maintenance dose) or to (2) ticagrelor (a 180 mg loading dose and a 90 mg twice daily maintenance dose). The predefined primary end point is infarct sieze on magnetic resonance imaging at the end of the study (6 months). Magnetic resonance will be performed at day 1, day 7 and moth 6. Platelet reactivity, biomarkers and clinical outcomes will also be assesed.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

ST Elevation Myocardial Infarction

Interventions

PrasugrelDRUG

60 mg oral bolus plus oral 10 mg once daily

TicagrelorDRUG

180 mg oral bolus plus oral 90 mg every 12 hours daily

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * age 18 years or older and equal or less than 75 years * symptom onset within 12 hours before random assignment * chest pain lasting more than 30 minutes * ST-segment elevation of at least 0.1 mV in at least 2 limb leads, ST-segment elevation of at least 0.2 mV in 2 or more contiguous precordial leads, or left bundle-branch block or paced rhythm * time from symptoms onset to randomization less than 6 hours * no severe heart failure (Killip class \<3) * informed, written consent Exclusion Criteria: * history of myocardial infarction with Q wave * history of surgical or percutaneous coronary revascularization * cardiogenic shock, defined as a systolic blood pressure \<90 mm Hg with no response to fluid administration or \<100 mm Hg in patients with supportive treatment and no bradycardia * history of stroke * history of bronchial asthma * symtomatic sinusal bradicardia or advance AV block * history of hypersensitivity to aspirin, prasugrel or ticagrelor or contraindication to the doses established in the study * patients pretreated with 600 mg of clopidogrel or more * contraindication for the use of gadolinium during the magenitc resonance

Locations (1)

Pedro Dorado

Salamanca, Spain

Outcomes

Primary Outcomes

Infarct size

Cardiac magnetic resonance imaging-assessed infarct size of left ventricular mass (%)

Time frame: 6 months

Secondary Outcomes

Infarct size

Cardiac magnetic resonance imaging-assessed infarct size of left ventricular mass (%)

Time frame: up to two weeks

Myocardial salvage index

Cardiac magnetic resonance imaging-assessed myocardial salvage index

Time frame: up to two weeks

Microvascular obstruction

Cardiac magnetic resonance imaging-assessed microvascular obstruction

Time frame: up to two weeks

MACE

The rate of MACE defined as the composite of death, reinfarction, new-onset heart failure, or rehospitalization

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.